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AbstrACt
Objective In Ghana, intermittent preventive treatment during 
pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is 
recommended for the prevention of malaria-related adverse 
outcomes. This study demonstrates the coverage of IPTp-SP 
use among pregnant women over a period (2011–2015) and 
the impact of various sociodemographic groups on the uptake 
of IPTp-SP.
Design Retrospective analysis using data from all pregnant 
women in the Kintampo Health and Demographic Surveillance 
System area on the uptake of IPTp-SP.
setting Kintampo North Municipality and Kintampo South 
District of Ghana.
Participants All pregnant women in the Kintampo Health and 
Demographic Surveillance System area.
Primary and secondary outcome measures The number of 
doses of IPTp-SP taken by pregnant women were examined. 
Logistic regression was used to assess the determinant 
of uptake of IPTp-SP while adjusting for within-subject 
correlation from women with multiple pregnancies.
results Data from 2011 to 2015 with a total of 17 484 
pregnant women were used. The coverage of the 
recommended three or more doses of IPTp-SP among all 
pregnant women was 40.6%, 44.0%, 45.9%, 20.9% and 
32.4% in 2011, 2012, 2013, 2014 and 2015, respectively. 
In the adjusted analysis, age, household size, education, 
religion, number of antenatal care visits, ethnicity, marital 
status, wealth index and place of residence were significantly 
associated with the uptake of three or more doses of IPTp-SP. 
Having middle school education or higher, aged 20 years and 
above, visiting antenatal care five times or more (OR 2.83, 
95% CI 2.64 to 3.03), being married (OR 1.10, 95% CI 1.02 to 
1.19) and those in higher wealth quintiles were significantly 
more likely to take three or more doses of IPTp-SP.
Conclusion The uptake of the recommended three or more 
doses of IPTp-SP is low in the study area. We recommend a 
community-based approach to identify women during early 
pregnancy and to administer IPTp-SP.
IntrODuCtIOn
Sub-Saharan Africa is the region that carries 
the heaviest malaria burden in the world.1 
Among pregnant women in the region, 
malaria is often the cause of mild to severe 
anaemia and placental parasitaemia.2 Malaria 
in pregnancy is also associated with low birth 
weight, as well as increase in the risk of peri-
natal mortality.2 Likewise, malaria infection 
during pregnancy is an important cause of 
spontaneous abortion and preterm delivery 
in the region.1 Due to the decreased immu-
nity during pregnancy, pregnant women are 
usually more vulnerable to malaria infec-
tion; it has been reported that they are 
four times more likely to get the disease and 
have a doubled chance of dying as a result of 
malaria.3 In Ghana, about 28% of all outpa-
tient department (OPD) attendance by preg-
nant women is due to malaria; about 13.7% of 
hospital admissions among pregnant women 
strengths and limitations of this study
 ► This study used data from the Kintampo Health and 
Demographic Surveillance System by including all 
identified pregnant women in the study area over a 
5-year period to assess how coverage of intermittent 
preventive treatment during pregnancy with sulpha-
doxine-pyrimethamine (IPTp-SP) has changed over 
the past few years.
 ► Also, because the entire population of pregnant 
women in the study area were included, there is no 
bias in terms of selection of respondents.
 ► The study findings can be generalised to the 
Kintampo Health and Demographic Surveillance 
System area and not the whole of Ghana.
 ► Although no pregnant woman refused participation, 
it is possible that a handful of pregnant women will 
be missed due to the approach used in identifying 
pregnant women.
 ► The study was limited to finding the maternal char-
acteristics associated with IPTp-SP.
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is a result of malaria, while 9% of maternal deaths is 
attributed to malaria.1 
Prevention and effective management of malaria 
during pregnancy helps in reducing the risk of poor 
outcomes for both mother and baby. For this reason, in 
the year 2000, the WHO recommended that pregnant 
women in malaria-endemic countries be given inter-
mittent preventive treatment (IPT) by taking sulpha-
doxine-pyrimethamine (SP) at least twice at scheduled 
antenatal visits from 16 weeks of gestation or at quick-
ening.1 Use of IPTp-SP among pregnant women has 
contributed to about 42% reduction in low birth weight, 
38% reduction in neonatal death and 65% reduction 
in placental malaria.4 However, the benefits of IPTp-SP 
have been found to be more pronounced when pregnant 
women take more doses. Taking three or more doses of 
IPTp-SP during pregnancy has been found to result in 
higher mean birth weight, fewer low birth weight as well 
as less placental malaria, compared with taking at most 
two doses.5 Based on these evidence, revisions were made 
by WHO in 2012 with recommendation of increasing the 
frequency of administering IPTp-SP to pregnant women 
at each antenatal care (ANC) visit until delivery.5 In 2013, 
the Ghana National Malaria Control Programme (NMCP) 
revised its policy, recommending at least three doses of 
IPTp-SP6 and have since 2014 been implementing it. The 
Ghana NMCP’s strategic plan for 2005–2015 had targeted 
that, by the year 2015, all pregnant women should receive 
two or more doses of IPTp-SP, which is now administered 
from 16 weeks of gestation onwards or at quickening and 
follow-up doses given on monthly basis.
Over the years, the coverage of at least three doses of 
IPTp –SP in Ghana has been on the increase, from 28% 
in 2008 to 60% in 2016.6 Regardless of the relatively 
high coverage in the uptake of three or more doses of 
SP by pregnant women in the country, the gap between 
uptake of only one dose of IPTp-SP and multiple doses 
remains significant. For instance, in 2016, the coverage 
of one dose of IPTp-SP was 85% compared with the 60% 
coverage of at least three doses of IPTp-SP.6
This manuscript reports the coverage of IPTp-SP among 
pregnant women and factors that are associated with the 
uptake of at least one dose and three or more doses of 
IPTp-SP using data collected between 2011 and 2015 as 
part of the Kintampo Health and Demographic Surveil-
lance System (KHDSS).7 The findings are expected to 
serve as evidence to guide the NMCP in the design of 
appropriate policies and strategies that can help increase 
the use of IPTp-SP and eventually reduce malaria-related 
adverse outcomes during pregnancy.
MethOD
study area and data description
Data from the KHDSS were used. The KHDSS, which 
is managed by the Kintampo Health Research Centre, 
routinely collects health data from residents of Kintampo 
North Municipality and Kintampo South District of 
Ghana. These are two contiguous districts located in the 
Brong Ahafo Region and lie in the geographical centre 
of the country.7 With a total population of about 154 341, 
it covers an area of 7162 square kilometres.8 There are 
2 hospitals, 5 private clinics, 13 health centres and 43 
community-based health planning and services that 
provide ANC and other healthcare need of the people. 
KHDSS routinely collects data on several events including 
pregnancies, births, deaths and migrations, as well as 
demographic information such as household socio-
economic status, education and causes of death among 
others.7
As part of the routine visits by the KHDSS, in 2011, 
2012 and 2013, all registered households were visited 
three times in a year in a cycle that gave rise to a visit in 
every 4 months. In 2014 and 2015, six monthly updated 
visits were made to all registered households. At each 
visit, household heads (or in the absence, an adult 
member of the household who was present) were asked 
by trained field workers if any member of their house-
hold was pregnant. Subsequently, identified pregnant 
women were interviewed by our trained field workers 
on a one-on-one basis without interference from other 
household members. Pregnancy registration forms that 
contained closed-ended questions were used to collect 
data on basic characteristics of respondents, pregnancy 
history and outcomes, use of antimalarial during preg-
nancy, insecticide-treated net (ITN) use and ANC atten-
dance records. Likewise, after birth, study participants 
were visited, and a birth registration form was used to 
document birth information and to also collect complete 
records of the pregnancy data. On the use of IPTp-SP, 
study participants were asked whether they took antima-
larial (IPTp-SP) at any ANC visit under the supervision of 
a healthcare attendant. Records on the number of times 
they received IPTp-SP and the corresponding dates of 
medication were transcribed from their ANC cards. All 
participants who were 18 years and above individually 
consented. For participants who were below 18 years, 
parental consent and assent were obtained. Participation 
was voluntary since individuals had the right to refuse to 
be part of the study before or during the interview.
Data on the use of IPTp-SP during pregnancy from 
2011 to 2015 were our main focus with the main outcome 
variable being the number of doses of IPTp-SP taken by 
each pregnant woman and was dichotomised as: (1) no 
dose versus at least one dose and (2) less than three doses 
versus three or more doses. For the predictor variables, 
maternal characteristics, namely, age, education, use of 
ITNs, religion, ethnicity, first or subsequent pregnancy, 
number of ANC visits, household size, place of residence 
(rural or urban), marital status and wealth index were 
used.
Patients and public involvement
The study did not recruit patients. Neither pregnant 
women nor the public were involved in the develop-
ment of the research question or design of this study. Key 
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stakeholder meeting will be organised to share the find-
ings with the community and Ghana Health Service who 
are in charge of healthcare delivery in the country.
statistical analysis
Cleaned data were analysed using STATA V.14.0. An 
overall wealth index was computed for each pregnant 
woman using principal component analysis as presented 
in Asante et al.9 The computation of the wealth index 
was based on the number and type of assets (such as 
televisions, cars, electricity, toilet facilities and house 
ownership) available in a pregnant woman’s household. 
Pregnant women were grouped by their wealth indices 
into wealth quintiles namely, poorest, more poor, poor, 
less poor and least poor. Sociodemographic character-
istics of the study participants were summarised using 
frequencies and percentages.
A univariate logistic regression model was considered 
for each of the predictor variables to study if they are 
independently associated with IPTp-SP use. Based on 
results of past studies,10–15 and interest in all the selected 
sociodemographic characteristics, we included all the 
predictor variables in a multiple logistic regression model 
regardless of their statistical significance in the univariate 
analysis. Two different analyses were performed. First, 
factors associated with the use of at least one dose of 
IPTp-SP were determined. This was followed by assessing 
the factors that were associated with the uptake of three 
or more doses of IPTp-SP. Considering the period under 
study, 21.3% of the study participants had more than one 
pregnancy. Hence, the data used for the analysis had 
repeated observations for participants who had more than 
one pregnancy between 2011 and 2015. In accounting 
for the fact that data from the same subject are not inde-
pendent, generalised estimating equation16 was used to 
obtain population-averaged estimates and to address the 
correlation present in the data. Robust SEs were obtained 
to alleviate the bias associated with possible misspeci-
fication of the correlation structure. With less than 8% 
missing data, complete case analysis was conducted by 
including subjects for whom all the variables involved in 
the analysis were observed.
results
Characteristics of the study population
A total of 17 484 pregnant women were identified from 
2011 to 2015. This was made up of 4065 pregnant women 
in 2011, 4570 in 2012, 4547 in 2013, 4295 in 2014 and 
3870 in 2015. All the identified pregnant women will-
ingly participated in the study. Over the 5-year period, 
78.68% (13 756/17 484) of the pregnant women 
contacted had one pregnancy; the remaining 21.32% 
(3728/17 484) who had multiple pregnancies were made 
up of 20.55% (3593/17 484) with two pregnancies and 
0.77% (135/17 484) with three pregnancies. Details of 
the characteristics of the study participants are presented 
in table 1.
Factors associated with uptake of at least one dose of IPtp-
sP
The coverage of at least one dose of IPTp-SP over the 
5-year period is presented in figure 1. There were signifi-
cantly higher coverage of at least one dose of IPTp-SP 
in 2012, 2013 and 2015, compared with 2011, but lower 
coverage in 2014 (table 2).
Table 2 presents the results of the association between 
all the maternal characteristics under study and the 
uptake of at least one dose of IPTp-SP. Age of mother, 
household size, education, religion, being pregnant for 
the first time, number of ANC visits, ethnicity, marital 
status and place of residence were independently associ-
ated with the use of IPTp-SP. However, in the adjusted 
analysis, factors that were significantly associated with the 
uptake of at least one dose of IPTp-SP were religion of 
participant, order of pregnancy, number of ANC visits, 
ethnicity and place of residence (table 2).
Factors associated with uptake of three or more doses of 
IPtp-sP
The coverage of the recommended three or more doses 
of IPTp-SP was 40.6%, 44.0%, 45.9%, 20.9% and 32.4% in 
2011, 2012, 2013, 2014 and 2015, respectively (figure 1). 
Compared with 2011, the coverage of three or more 
doses of IPTp-SP was significantly lower in 2014 and 2015. 
However, for 2012 and 2013, the coverage of three or 
more doses of IPTp-SP was significantly higher compared 
with the coverage in 2011 (table 3).
All the maternal characteristics under study were inde-
pendently associated with the uptake of the recommended 
three or more doses of IPTp-SP (table 3). Howver, after 
adjusting for all other factors, being pregnant for the first 
time and use of ITNs were not significantly associated 
with the uptake of three or more doses of IPTp-SP. The 
detailed results of the factors associated with the uptake 
of three or more doses of IPTp-SP is presented in table 3.
DIsCussIOn
The coverage of IPTp-SP, as well as the maternal char-
acteristics associated with the use of at least one dose of 
IPTp-SP and three or more doses of IPTp-SP was assessed 
among pregnant women in Kintampo North Munici-
pality and Kintampo South District of Ghana. The target 
set by Ghana National Malaria Control Program was for 
all pregnant women to be on IPTp-SP by the year 2015.17 
Although the coverage of at least one dose of IPTp-SP 
has remained high, the target set by the Ghana National 
Malaria Control Program was not achieved in Kintampo 
North Municipality and Kintampo South District.
Compared with the coverage of at least one dose of 
IPTp-SP, the coverage of the recommended three or more 
doses of IPTp-SP was lower. Also, there was no significant 
increase in the uptake of the recommended three or 
more doses of IPTp-SP after the implementation of the 
new policy, which required pregnant women to take at 
least three doses of IPTp-SP.6 Rather, the coverage of at 
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Table 1 Characteristics of study subjects by year of interaction
Variable
Year
2011 (n=4065) 2012 (n=4570) 2013 (n=4547) 2014 (n=4295) 2015 (n=3870)
Age of mother (years)
12–19 12.18 (495) 12.21 (558) 12.93 (588) 13.36 (574) 13.00 (503)
20–29 45.98 (1869) 46.74 (2136) 49.44 (2248) 47.10 (2023) 44.13 (1708)
30–39 34.49 (1402) 34.49 (1576) 32.31 (1469) 33.20 (1426) 35.45 (1372)
≥40 7.36 (299) 6.56 (300) 5.32 (242) 6.33 (272) 7.42 (287)
*Household size
One member 14.46 (588) 17.51 (800) 19.51 (887) 18.39 (790) 18.60 (720)
Small 29.25 (1189) 28.71 (1312) 28.83 (1311) 30.31 (1302) 29.66 (1148)
Medium 40.54 (1 648) 38.99(1782) 37.39 (1700) 37.58 (1614) 37.13 (1437)
Large 15.74 (640) 14.79 (676) 14.27 (649) 13.71 (589) 14.60 (565)
†Education
No formal education 53.11 (2159) 50.61 (2313) 47.57 (2163) 44.75 (1922) 43.02 (1665)
Primary 23.30 (947) 24.38 (1114) 25.62 (1165) 25.96 (1115) 26.05 (1008)
Middle/JHS 19.43 (790) 20.94 (957) 21.35 (971) 22.93 (985) 24.52 (949)
Secondary+ 4.16 (169) 4.07 (186) 5.45 (248) 6.36 (273) 6.41 (248)
Religion
Christian 55.60 (2260) 54.20 (2477) 54.52 (2479) 53.81 (2311) 56.98 (2205)
Muslims 29.69 (1207) 29.43 (1345) 28.79 (1309) 31.04 (1333) 29.25 (1132)
Traditional 2.48 (101) 2.76 (126) 2.49 (113) 2.84 (122) 2.53 (98)
No religion 6.67 (271) 6.59 (301) 6.55 (298) 6.82 (293) 6.69 (259)
Missing data 5.56 (226) 7.02 (321) 7.65 (348) 5.49 (236) 4.55 (176)
First pregnancy 25.39 (1032) 24.90 (1138) 25.12 (1142) 25.26 (1085) 22.25 (861)
Use of ITNs 54.51 (2216) 65.69 (3002) 77.68 (3532) 80.23 (3446) 77.83 (3012)
Number of ANC visits
0 or 1 visit 6.99 (284) 6.39 (292) 7.15 (325) 6.43 (276) 7.05 (273)
2–4 visits 44.94 (1827) 44.73 (2044) 44.64 (2030) 44.77 (1923) 42.95 (1662)
5 or more visits 48.07 (1954) 48.88 (2234) 48.21 (2192) 48.80 (2096) 50.00 (1935)
‡Ethnicity
Akan 19.58 (796) 20.63 (943) 20.23 (920) 20.84 (895) 21.14 (818)
Northern Tribes 57.96 (2356) 57.40 (2623) 57.69 (2623) 57.88 (2486) 57.78 (2236)
Mo 12.05 (490) 10.96 (501) 11.55 (525) 11.94 (513) 12.07 (467)
Others 7.77 (316) 7.59 (347) 6.82 (310) 7.22 (310) 6.87 (266)
Missing data 2.63 (107) 3.41 (156) 3.72 (169) 2.12 (91) 2.14 (83)
Marital status
Married 48.51 (1972) 47.35 (2164) 45.22 (2056) 43.66 (1875) 45.40 (1757)
Not married 51.49 (2093) 52.65 (2406) 54.78 (2491) 56.34 (2420) 54.60 (2113)
Wealth index
Poorest 25.58 (1040) 21.49 (982) 20.91 (951) 15.37 (660) 20.70 (801)
More poor 23.30 (947) 21.18 (968) 21.33 (970) 19.23 (826) 21.42 (829)
Poor 22.16 (901) 20.57 (940) 20.67 (940) 19.09(820) 19.77 (765)
Less poor 17.93 (729) 19.50 (891) 19.68 (895) 19.72 (847) 19.92 (771)
Least poor 10.80 (439) 16.98 (776) 17.29 (786) 26.33 (1131) 17.83 (690)
Missing data 0.22 (9) 0.28 (13) 0.11 (5) 0.26 (11) 0.36 (14)
Place of residence
Continued
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least one dose as well as three or more doses of IPTp-SP 
in 2014 and 2015 was lower compared with the period 
preceding the implementation of the new policy. The 
low coverage of the recommended three or more doses 
of IPTp-SP has also been reported in other parts of the 
country.18–20 Challenges associated with the implementa-
tion of the new policy may have contributed to the low 
IPTp-SP coverage in 2014 and 2015. In 2014, transpor-
tation challenges as well as delays in allocating malaria 
commodities affected the distribution of SP to most 
periphery facilities in Ghana. This resulted in artificial 
stock outs of SP in several facilities within the country.21 22 
To help improve coverage, Ghana NMCP should ensure 
that at all times, all heath facilities in the country have SP 
in stock. Also, the low uptake of the recommended three 
or more doses of IPTp-SP compared with the national 
coverage could be due to contextual factor that might 
have influenced the implementation of the new policy. 
There is the need to further explore these contextual 
factors. However, this finding emphasises the variations 
in IPTp uptake in Ghana and the need for context-spe-
cific interventions especially in rural settings such as the 
study area.
Several maternal sociodemographic characteristics 
were found to be associated with the uptake of at least 
one dose of IPTp-SP. With regards to order of pregnancy, 
as expected, women who have subsequent pregnancies 
were more likely to take at least one dose of IPTp-SP. This 
may be due to their knowledge and education on the 
benefits of IPTp-SP gained from previous pregnancies. 
Undoubtedly, frequency of ANC attendance was found to 
be significantly associated with the uptake of at least one 
dose of IPTp-SP. This is not surprising given that IPTp-SP 
is a directly observed therapy administered during ANC 
visits.
The low uptake of the recommended three or more 
doses of IPTp-SP among teenage participants compared 
with older participants can be attributed to the low 
patronage of ANC among teenagers. Due to the stigma 
associated with teenage pregnancy in Ghana, pregnant 
teenagers are less likely to go for ANC compared with 
older pregnant women.23 24 Often, teenagers hide their 
pregnancies and delay in ANC attendance24 and are 
therefore not able to take the recommended doses before 
they deliver. Given the increased risks faced by pregnant 
adolescents, we recommend that ANC clinics in the study 
area should be made adolescent friendly and should also 
integrate health education on the benefits of ANC visits 
and uptake of IPTp-SP. Likewise, parents and guardians 
should assist pregnant adolescents and encourage them 
to attend ANC as well as to educate them on the burden 
of malaria infection during pregnancy and the need to 
take the recommended number IPTp-SP doses.
Similar to the results on the uptake of at least one dose 
of IPTp-SP, the number of times a woman attends ANC 
was significantly associated with the uptake of the recom-
mended three or more doses of IPTp-SP. A pregnant 
woman can only take the recommended three or more 
doses of IPTp-SP if she attends ANC at least three times. 
In Ghana, it is recommended for all pregnant women to 
attend ANC at least four times.5 23 Even so, the new policy 
on the uptake of IPTp-SP recommends that starting as 
early as the beginning of the second trimester of preg-
nancy, SP should be administered at each scheduled ANC 
visit until delivery. Likewise, the policy stipulates that 
except in the first trimester, IPTp-SP can be administered 
every month with subsequent doses given at least 1 month 
apart. This implies that more doses of IPTp-SP are recom-
mended. Given these recommendations, it is important 
Variable
Year
2011 (n=4065) 2012 (n=4570) 2013 (n=4547) 2014 (n=4295) 2015 (n=3870)
Rural 68.29 (2776) 64.81 (2962) 65.60 (2983) 66.78 (2868) 66.72 (2582)
Urban 31.71 (1289) 35.19 (1608) 34.40 (1564) 33.22 (1427) 33.28 (1288)
Data are presented as percentage (frequency).
*Small (2–4 people), medium (5–10 people) and large (more than 10 people).
†Secondary+ (secondary school education or higher) and junior high school (JHS).
‡Northern tribes (tribes from any of the three Northern regions of Ghana) and other (any other ethnic group).
ANC, antenatal care; JHS, junior high school; ITNs, insecticide-treated net.
Table 1 Continued 
Figure 1 Doses of IPTp-SP taken by pregnant women 
in the Kintampo North Municipality and Kintampo 
South District from 2011 to 2015. IPTp-SP, intermittent 
preventive treatment during pregnancy with sulphadoxine-
pyrimethamine.
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Table 2 Factors associated with use of at least one dose of IPTp-SP
Predictor Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age of mother (years)
12–19 1 1
20–29 1.12 (1.01 to 1.25) 0.044 1.00 (0.87 to 1.15) 0.999
30–39 1.22 (1.09 to 1.37) 0.001 1.06 (0.90 to 1.25) 0.485
≥40 1.11 (0.93 to 1.31) 0.242 1.01 (0.81 to 1.24) 0.959
Household size
One member 1 1
Small 0.95 (0.85 to 1.06) 0.350 1.00 (0.88 to 1.12) 0.939
Medium 0.87 (0.78 to 0.97) 0.010 0.98 (0.87 to 1.11) 0.795
Large 0.90 (0.79 to 1.03) 0.120 1.03 (0.89 to 1.19) 0.698
Education
None 1 1
Primary 1.06 (0.97 to 1.16) 0.220 1.01 (0.91 to 1.13) 0.803
Middle/JHS 1.18 (1.07 to 1.30) 0.001 1.08 (0.95 to 1.22) 0.227
Secondary+ 0.99 (0.84 to 1.16) 0.874 0.85 (0.69 to 1.03) 0.101
Religion
Christian 1 1
Muslims 0.89 (0.82 to 0.96) 0.005 0.86 (0.78 to 0.95) 0.003
Traditional 1.02 (0.81 to 1.29) 0.844 1.20 (0.93 to 1.53) 0.158
No religion 0.88 (0.76 to 1.02) 0.091 0.98 (0.83 to 1.15) 0.771
First pregnancy
No 1 1
Yes 0.86 (0.79 to 0.93) <0.001 0.84 (0.75 to 0.94) 0.002
Use of ITNs
No 1
Yes 1.02 (0.94 to 1.10) 0.624 1.05 (0.96 to 1.15) 0.261
Number of ANC visits
0 or 1 visit 1
2–4 visits 8.71 (7.71 to 9.82) <0.001 8.87 (7.80 to 10.08) <0.001
5 or more visits 5.48 (4.88 to 6.15) <0.001 5.22 (4.60 to 5.92) <0.001
Ethnicity
Akan 1 1
Northern Tribes 0.93 (0.85 to 1.02) 0.128 1.05 (0.93 to 1.18) 0.475
Mo 1.18 (1.03 to 1.35) 0.020 1.19 (1.03 to 1.39) 0.021
Others 0.92 (0.79 to 1.07) 0.295 0.93 (0.78 to 1.12) 0.456
Marital status
Not married 1 1
Married 1.10 (1.02 to 1.18) 0.012 1.01 (0.92 to 1.11) 0.842
Wealth index
Poorest 1
More poor 1.05 (0.94 to 1.17) 0.374 1.11 (0.98 to 1.26) 0.099
Poor 1.08 (0.96 to 1.21) 0.182 1.09 (0.96 to 1.24) 0.171
Less poor 1.07 (0.96 to 1.20) 0.218 1.07 (0.94 to 1.22) 0.299
Least poor 1.03 (0.92 to 1.16) 0.608 1.04 (0.91 to 1.19) 0.566
Place of residence
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for pregnant women to initiate ANC visit as early as 
possible in order to be able take the required doses of SP.
Strategies such as Transforming IPT for Optimal Preg-
nancy (TIPTOP) initiative can be adopted in the study 
area to help increase IPTp-SP coverage. The approach 
of TIPTOP involves engaging community health volun-
teers to identify women during early stages of pregnancy, 
to educate them on the benefits of early ANC attendance 
and IPTp-SP use and to refer them to a health facility for 
ANC. Also, with the goal of increasing IPTp-SP coverage, 
volunteers of the TIPTOP initiative distribute SP to preg-
nant women at the community level.25 This approach 
to administering IPTp-SP will help increase coverage by 
reaching out to all pregnant women irrespective of their 
sociodemographic characteristic. In a study conducted in 
Uganda, community-based delivery of IPTp-SP was found 
to increase IPTp-SP coverage. Also, the administration of 
IPTp-SP at the community level resulted in a reduction in 
the prevalence of malaria parasitaemia, severe anaemia 
and low birth weight and was acceptable to about 90% of 
women who intend to use SP in the future.26 In addition 
to this approach, studies have reported that provision of 
incentives to pregnant women during ANC visits is asso-
ciated with an increase in ANC attendance.27 28 Hence, 
we propose the provision of some form of non-monetary 
incentives to pregnant women who attend all scheduled 
ANC visits to help motivate other pregnant women to 
attend all scheduled ANC which may eventually lead to 
an increase in the coverage of IPTp-SP.
The low uptake of the recommended three or 
more doses of IPTp-SP among unmarried participants 
compared with married participants could be attributed 
to the possible support that married women get from 
their partners during pregnancy. In most rural settings 
in Ghana such as our study area, women largely depend 
on their husbands for financial support in seeking health-
care.29 Married women may have received the neces-
sary financial support to travel to attend ANC for the 
recommended three or more doses of IPTp-SP consid-
ering that frequency of ANC attendance was associated 
with uptake of the recommended doses of IPTp-SP. The 
high uptake of the recommended three or more doses 
of IPTp-SP among educated participants compared with 
those with no formal education can also be attributed to 
how informed women with formal education are about 
the increased risk of malaria infection during pregnancy 
and the complications associated with malaria during 
pregnancy.30 This further reiterates the significant role 
education plays with regards to the use of health interven-
tions.30 Other studies in Ghana10 and other parts of Africa 
including Uganda12 and Kenya13 14 also reported an asso-
ciation between education and the uptake IPTp-SP.
One would expect that due to the knowledge gained 
from past pregnancies on the importance of malaria 
prevention during pregnancy and the benefits of IPTp-
SP, women with history of past pregnancies will take the 
recommended three or more doses of IPTp-SP. However, 
even though participants who were pregnant for the first 
time were less likely to take at least one dose of IPTp-SP, 
there was no significant association between history of 
past pregnancy and uptake of the recommended three 
or doses of IPTp-SP. Other studies in Ghana31 and other 
parts of Africa including Nigeria32 and Cameroon33 have 
also reported no association between subsequent preg-
nancies and uptake of the recommended doses of IPTp-
SP. In Ghana, association has been reported between 
wealth and health, such that people with better socio-
economic status have better health-seeking behaviour.34 
This is reiterated in this study given that women in the 
higher wealth quintiles are more likely to take the recom-
mended three or more doses of IPTp-SP. Even though 
IPTp-SP is provided to pregnant women free of charge, 
they are only given to women when they visit a health 
facility for ANC care. Sometimes, cost/means of transpor-
tation to the nearest ANC clinic prevent pregnant women 
from attending ANC.24 35 36 As such, women in the higher 
wealth quintiles are more likely to attend ANC since they 
may be able to bear the cost of visit to ANC clinics.36 This 
result is similar to that reported in the most recent Ghana 
Demographic and Health Survey in which the coverage 
of the recommended three or more doses of IPTp-SP was 
50.6% and 36.6% among women in the highest wealth 
Predictor Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Rural 1 1
Urban 1.50 (1.39 to 1.63) <0.001 1.56 (1.42 to 1.72) <0.001
Year
2011 1 1
2012 1.28 (1.14 to 1.43) <0.001 1.24 (1.10 to 1.41) 0.001
2013 1.48 (1.32 to 1.66) <0.001 1.50 (1.32 to 1.70) <0.001
2014 0.77 (0.69 to 0.86) <0.001 0.72 (0.64 to 0.81) <0.001
2015 1.21 (1.08 to 1.36) 0.001 1.19 (1.05 to 1.36) 0.008
IPTp-SP, intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine.
ANC, antenatal care; JHS, junior high school; ITNs, insecticide-treated nets.
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Table 3 Factors associated with the uptake of three or more doses of IPTp-SP
Predictor Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age of mother (years)
12–19 1 1
20–29 1.49 (1.35 to 1.64) <0.001 1.28 (1.13 to 1.45) <0.001
30–39 1.46 (1.32 to 1.61) <0.001 1.35 (1.17 to 1.56) <0.001
≥40 1.15 (0.99 to 1.33) 0.063 1.27 (1.05 to 1.53) 0.013
Household size
One member 1 1
Small 0.92 (0.84 to 1.00) 0.054 1.01 (0.91 to 1.12) 0.817
Medium 0.70 (0.64 to 0.76) <0.001 0.83 (0.75 to 0.91) <0.001
Large 0.68 (0.61 to 0.75) <0.001 0.87 (0.77 to 0.99) 0.029
Education
None 1 1
Primary 1.18 (1.10 to 1.27) <0.001 1.05 (0.96 to 1.15) 0.288
Middle/JHS 1.53 (1.42 to 1.65) <0.001 1.17 (1.05 to 1.29) 0.003
Secondary+ 2.23 (1.94 to 2.56) <0.001 1.31 (1.10 to 1.56) 0.002
Religion
Christian 1 1
Muslims 0.74 (0.69 to 0.80) <0.001 0.83 (0.76 to 0.90) <0.001
Traditional 0.59 (0.48 to 0.71) <0.001 0.83 (0.67 to 1.02) 0.082
No religion 0.64 (0.56 to 0.72) <0.001 0.83 (0.72 to 0.95) 0.007
First pregnancy
No 1 1
Yes 1.09 (1.01 to 1.16) 0.018 1.07 (0.97 to 1.18) 0.170
Use of ITNs
No 1 1
Yes 0.87 (0.81 to 0.92) <0.001 1.07 (0.99 to 1.16) 0.076
Number of ANC visits
0 or 1 visit - -
2–4 visits 1 1
5 or more visits 3.04 (2.85 to 3.23) <0.001 2.83 (2.64 to 3.03) <0.001
Ethnicity
Akan 1 1
Northern Tribes 0.62 (0.57 to 0.67) <0.001 0.87 (0.79 to 0.97) 0.010
Mo 0.90 (0.81 to 1.01) 0.062 0.97 (0.86 to 1.10) 0.646
Others 0.73 (0.64 to 0.83) <0.001 0.77 (0.66 to 0.90) 0.001
Marital status
Not married 1 1
Married 1.09 (1.02 to 1.15) 0.008 1.10 (1.02 to 1.19) 0.015
Wealth index
Poorest 1 1
More poor 0.98 (0.89 to 1.08) 0.667 1.03 (0.93 to 1.15) 0.526
Poor 1.22 (1.11 to 1.34) <0.001 1.28 (1.15 to 1.43) <0.001
Less poor 1.31 (1.19 to 1.44) <0.001 1.25 (1.12 to 1.40) <0.001
Least poor 1.40 (1.27 to 1.54) <0.001 1.32 (1.17 to 1.49) <0.001
Place of residence
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quintile and those in the lowest quintile, respectively.37 
Also, similar results have been reported in Senegal,38 
where women in richer or middle wealth quintile were 
more likely to use the recommended doses of IPTp.
It should be emphasised that the use of data from Health 
and Demographic Surveillance Systems can be of great 
importance in informing policy makers of challenges in 
several health interventions. Particularly, this study used 
the KHDSS by including all identified pregnant women 
in the study area over a 5-year period. Unlike the results 
of cross-sectional studies, the use KHDSS has made it 
possible to assess and compare the coverage of IPTp-SP 
over a 5-year period. It is also important to note that, with 
the use of data from all 156 communities of the KHDSS, 
the study findings can be generalised to all the KHDSS 
area and not the whole of Ghana. Also, because this study 
used the entire population of pregnant women, there is 
no bias in terms of selection of respondents. Although no 
pregnant woman refused participation, it is possible that 
a handful of pregnant women will be missed due to the 
approach used in identifying pregnant women. Also, the 
study was limited to finding the maternal characteristics 
associated with IPTp-SP use.
COnClusIOn
The use of at least one dose of IPTp-SP in the KHDSS area 
is generally high. However, uptake of the recommended 
three or more doses of IPTp-SP remains low. The study 
has found that the most vulnerable pregnant women are 
less likely to take the recommended three or more doses 
of IPTp-SP. The study therefore recommends the adop-
tion of the TIPTOP strategy to help improve the coverage 
of IPTp-SP in the study area.
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